Blockade of angiotensin II type-1 receptor increases salt sensitivity in Sprague-Dawley rats

Hypertension Research

Volumn 32, Issue 6, 2009, Pages 513-519

  Endo, Satoshi ^a   Mori, Takefumi ^a,b   Yoneki, Yoshimi ^a   Nakamichi, Takashi ^a   Hosoya, Takuma ^a   Ogawa, Susumu ^a   Tokudome, Goro ^c   Hosoya, Tatsuo ^c   Miyata, Toshio ^a   Ito, Sadayoshi ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

^c JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; HYDROCHLOROTHIAZIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; OLMESARTAN;

ANIMAL EXPERIMENT; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; ENZYME ACTIVITY; HYPERTENSION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; OXIDATIVE STRESS; PROTEIN FUNCTION; RAT; SALT INTAKE; SALT SENSITIVITY; SENSITIVITY ANALYSIS; SPRAGUE DAWLEY RAT; TELEMETRY; URINALYSIS;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BIOLOGICAL MARKERS; BLOOD PRESSURE; CIRCADIAN RHYTHM; DIURETICS; IMIDAZOLES; MALE; NADPH OXIDASE; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; SODIUM; SODIUM, DIETARY; TELEMETRY; TETRAZOLES;

EID: 68249156747     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2009.40     Document Type: Article

References (33)

1. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S,Ménard J, Rahn KH, Wedel H, Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-1762.
2. Morimoto S, Yano Y, Maki K, Sawada K. Renal and vascular protective effects of telmisartan in patients with essential hypertension. Hypertens Res 2006; 29: 567-572.
3. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002; 359: 995-1003.
4. Herlitz H, Dahlof B, Jonsson O, Friberg P. Relationship between salt and blood pressure in hypertensive patients on chronic ACE-inhibition. Blood Press 1998; 7: 47-52.
5. Fang Z, Sripairojthikoon W, Calhoun DA, Zhu S, Berecek KH, Wyss JM. Interaction between lifetime captopril treatment and NaCI-sensitive hypertension in spontaneously hypertensive rats and Wistar-Kyoto rats. J Hypertens 1999; 17: 983-991.
6. Xu L, Brooks VL. Sodium intake, angiotensin II receptor blockade, and baroreflex function in conscious rats. Hypertension 1997; 29 450-457.
7. Shimosawa T, Gohchi K, Yatomi Y, Fujita T. Effectiveness of add-on low-dose diuretics in combination therapy for hypertension: Losartan/ hydrochlorothiazide vs candesartan/amlodipine. Hypertens Res 2007; 30: 831-837.
8. Weir MR, Smith DH, Neutel JM, Bedigian MP. Valsartan alone or with a diuretic or ACE inhibitor as treatment for African American hypertensives: Relation to salt intake. Am J Hypertens 2001; 14 665-671.
9. Vogt L, Waanders F, Boomsma F, de Zeeuw D, Navis G. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol 2008; 19: 999-1007.
10. Hall JE, Guyton AC, Smith Jr MJ, Coleman TG. Long-term regulation of arterial pressure, glomerular filtration and renal sodium reabsorption by angiotensin II in dogs. Clin Sci (Lond) 1980; 59: 87-90.
11. Unger T, Chung O, Csikos T, Culman J, Gallinat S, Gohlke P, Höhle S, Meffert S, Stoll M, Stroth U, Zhu YZ. Angiotensin receptors. J Hypertens Suppl 1996; 14: S95-S103.
12. 2 leads to hypertension. Hypertension 2003; 42: 25-30.
13. Kitiyakara C, Chabrashvili T, Chen Y, Blau J, Karber A, Aslam S, Welch WJ, Wilcox CS. Salt intake, oxidative stress, and renal expression of NADPH oxidase and superoxide dismutase. J Am Soc Nephrol 2003; 14: 2775-2782.
14. Guo P, Nishiyama A, Rahman M, Nagai Y, Noma T, Namba T, Ishizawa M, Murakami K, Miyatake A, Kimura S, Mizushige K, Abe Y, Ohmori K, Kohno M. Contribution of reactive oxygen species to the pathogenesis of left ventricular failure in Dahl salt-sensitive hypertensive rats: Effects of angiotensin II blockade. J Hypertens 2006; 24: 1097-1104.
15. Cowley Jr AW. Long-term control of arterial blood pressure. Physiol Rev 1992; 72: 231-300.
16. Kimura G, Saito F, Kojima S, Yoshimi H, Abe H, Kawano Y, Yoshida K, Ashida T, Kawamura M, Kuramochi M. Renal function curve in patients with secondary forms of hypertension. Hypertension 1987; 10: 11-15.
17. Cowley Jr AW, Mori T, Mattson D, Zou AP. Role of renal NO production in the regulation of medullary blood flow. Am J Physiol Regul Integr Comp Physiol 2003; 284: 1355-1369.
18. Oliverio MI, Best CF, Smithies O, Coffman TM. Regulation of sodium balance and blood pressure by the AT(1A) receptor for angiotensin II. Hypertension 2000; 35: 550-554.
19. Gross V, Milia AF, Plehm R, Inagami T, Luft FC. Long-term blood pressure telemetry in AT2 receptor-disrupted mice. J Hypertens 2000; 18 955-961.
20. Uzu T, Kimura G, Yamauchi A, Kanasaki M, Isshiki K, Araki S, Sugiomoto T, Nishio Y, Maegawa H, Koya D, Haneda M, Kashiwagi A. Enhanced sodium sensitivity and disturbed circadian rhythm of blood pressure in essential hypertension. J Hypertens 2006; 24: 1627-1632.
21. Schnecko A, Witte K, Lemmer B. Effects of the angiotensin II receptor antagonist losartan on 24-h blood pressure profiles of primary and secondary hypertensive rats. J Cardiovasc Pharmacol 1995; 26 214-221.
22. Sachdeva A, Weder AB. Nocturnal sodium excretion, blood pressure dipping, and sodium sensitivity. Hypertension 2006; 48: 527-533.
23. Hermida RC, Calvo C, Ayala DE, Fernández JR, Covelo M, Mojón A, López JE. Treatment of non-dipper hypertension with bedtime administration of valsartan. J Hypertens 2005; 23: 1913-1922.
24. Van den Buuse M. Circadian rhythms of blood pressure, heart rate, and locomotor activity in spontaneously hypertensive rats as measured with radio-telemetry. Physiol Behav 1994; 55: 783-787.
25. Fukuda M, Yamanaka T, Mizuno M, Motokawa M, Shirasawa Y, Miyagi S, Nishio T, Yoshida A, Kimura G. Angiotensin II type 1 receptor blocker, olmesartan, restores nocturnal blood pressure decline by enhancing daytime natriuresis. J Hypertens 2008; 26: 583-588.
26. Mori T, Cowley Jr AW, Ito S. Molecular mechanisms and therapeutic strategies of chronic renal injury: Physiological role of angiotensin II-induced oxidative stress in renal medulla. J Pharmacol Sci 2006; 100: 2-8.
27. Uzu T, Kimura G. Diuretics shift circadian rhythm of blood pressure from nondipper to dipper in essential hypertension. Circulation 1999; 100: 1635-1638.
28. Taylor NE, Glocka P, Liang M, Cowley Jr AW. NADPH oxidase in the renal medulla causes oxidative stress and contributes to salt-sensitive hypertension in Dahl S rats. Hypertension 2006; 47: 692-698.
29. Mori T, Cowley Jr AW. Angiotensin II-NAD(P)H oxidase-stimulated superoxide modifies tubulovascular nitric oxide cross-talk in renal outer medulla. Hypertension 2003; 42: 588-593.
30. Mori T, O'Connor PM, Abe M, Cowley Jr AW. Enhanced superoxide production in renal outer medulla of Dahl salt-sensitive rats reduces nitric oxide tubular-vascular cross-talk. Hypertension 2007; 49: 1336-1341.
31. Pech V, Sikka SC, Sindhu RK, Vaziri ND, Majid DS. Oxidant stress and blood pressure responses to angiotensin II administration in rats fed varying salt diets. Am J Hypertens 2006; 19: 534-540.
32. Reungjui S, Hu H, Mu W, Roncal CA, Croker BP, Patel JM, Nakagawa T, Srinivas T, Byer K, Simoni J, Wesson D, Sitprija V, Johnson RJ. Thiazide-induced subtle renal injury not observed in states of equivalent hypokalemia. Kidney Int 2007; 72: 1483-1492.
33. Ogawa S, Mori T, Nako K, Kato T, Takeuchi K, Ito S. Angiotensin II type 1 receptor blockers reduce urinary oxidative stress markers in hypertensive diabetic nephropathy. Hypertension 2006; 47: 699-705.